Marco Meglio

Patients on IPX203 received less doses than those on traditional immediate-release carbidopa/levodopa and demonstrated 0.53 more hours of good ON time per day than IR CD/LD.

Over the 36-month treatment period, nonambulatory patients with SMA treated with apitegromab showed improvements in patient-reported outcomes of daily living and fatigue.

Although the association between genetically predicted insomnia and risk of sepsis was mediated through cardiometabolic risk factors, the data still point to a clear link between the two conditions.

The neurosurgeon at Allegheny Health Network provided perspective on how GammaTile therapy is revolutionizing neurosurgery and post-operative processes of brain tumors.

At 6 weeks post-treatment, the patient saw clinical improvements in multiple domains, including autonomic function, vocalization, gross motor skills, and fine motor skills and hand function.

In a phase 3 study and open-label extension, patients treated with daxibotulinumtoxinA showed significant improvements in their condition, explained by changes on the Toronto Western Spasmodic Torticollis Rating Scale.

In addition to showing a safe and tolerable safety profile, patients who underwent the procedure showed a 7-point median improvement on the upper extremity Fugl-Meyer Assessment when used in combination with physical rehabilitation.

Results indicated a substantial direct effect of air pollution on dementia suggesting that air pollution affects the development of dementia through multiple pathways.

Stroke of an undetermined cause was associated with acute symptomatic seizures, an effect that was marginally mediated by cerebral microbleeds.

Patients treated with the neuromodulation device outperformed those on placebo on several key outcomes, including Visual Analog Scale and Migraine-Specific Quality of Life Questionnaire scores.

UB-311 elicited a robust, rapid, and titrated antibody response to amyloid-ß, with an overall 97% responder rate that was maintained by 93% of the cohort by the end of the 78-week study.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Thomas Crawford, MD. [LISTEN TIME: 24 minutes]

Pharmacokinetic results indicated that ACD856 has a suitable pharmacokinetic profile for further development with a rapid absorption, dose-dependent exposure, and a favorable metabolic profile.

The double-blind, placebo-controlled trial assesses change from baseline in the weekly average of daily self-reported worst pain intensity scores after 14 weeks of treatment.

Patients who continued on active treatment into the open-label extension saw continued improvements in their condition after 14 weeks.

Results showed that 67% of treated patients in Stage A demonstrated evidence of clinical improvement, indicating that IgG autoantibodies play a significant role in the underlying biology of CIDP.

In a large-scale, nationwide cohort, the impact of migraine on risk of premature myocardial infarction was slightly greater for women and may potentially only exist for women.

The executive vice president of the National MS Society provided insight on the Pathways to Cures roadmap, a global initiative to stop multiple sclerosis, restore function, and end MS.

In comparison with placebo, older adults on low-dose aspirin had an increase in a combination of subdural, extradural, and subarachnoid bleeding.

Concentrations of Aß42 and Aß40 were substantially higher in those with amyloid-ß-negative, tau-positive status compared with Aß-negative, tau-negative patients.

With the decision, ClarityPro becomes the first and only device to offer new technology add-on payment reimbursement for the diagnosis of electrographic status epilepticus.

The trial is expected to include 14 individuals with genetically confirmed limb-girdle muscular dystrophy who will be randomly assigned 1:1 to either AB-1003 or placebo for a year-long treatment period.

In the supporting phase 3 study, treatment with GA Depot resulted in statistically significant reductions in annualized relapse rate, the primary end point, and other secondary outcomes of T1 and T2 hyperintense lesions.

The time to osteoporosis was 23% faster with exposure to non-enzyme-inducing antiseizure medications and 9% faster for enzyme-inducing ASMs, independent of epilepsy.

Although treatment with tirofiban improved the odds of excellent outcome, results for the secondary end points did not consistently support the primary end point analysis.

After nearly 13 years of follow-up, 36% of patients with relapsing multiple sclerosis had a confirmed Expanded Disability Status Scale score worsening.

The combination of digital cognitive behavioral therapy and medication resulted in a sustained improvement in sleep quality compared with monotherapy modalities.

Because its gut-acting and gut-restricted, the safety profile of DGX-001 was considered advantageous in comparison to traditional neuropsychiatric therapies.

The pediatric neurologist at Johns Hopkins Medicine provided clarity on the recently published 5-year update of the NURTURE study, and the importance of treating spinal muscular atrophy at its presymptomatic stages.

Sleep stage percentages were not associated with global cognition across cohorts, while patients with mild to severe OSA displayed poorer global cognitive function.